Assess efficacy, safety, and cost of alternate-day dosing with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (HRIs).
DATA:
International Pharmaceutical Abstracts and MEDLINE (English-language clinical trials, 1966–April 2000) were searched.
DATA SYNTHESIS:
Established efficacy of HRIs is based on daily administration. Many patients who could benefit from these agents are unable to afford them; therefore, alternate-day dosing may be a solution for reducing expense without decreasing therapy benefits. Studies addressing alternate-day HRI therapy are evaluated to determine the usefulness of this option for cholesterol reduction.
CONCLUSIONS:
Although limited studies imply a trend toward benefit with alternate-day HRI therapy, large, controlled, randomized trials are needed before making this a standard recommendation.
LeeTHCleemanJIGrundySMGillettCPasternakRCSeidmanJClinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA2000;283:94–8.
2.
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA1993;269:3015–23.
3.
StamlerJWentworthDNeatonJD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA1986;256:2823–8.
4.
CasteliWPGarrisonRJWilsonPWFAbbottRDKalousdianSKannelWB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study. JAMA1986;256:2835–8.
5.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet1994;344:1383–9.
6.
SheperdJCobbeSMFordIIslesCGLorimerARMacFarlanePWPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995;333:1301–7.
7.
DownsJRClearfieldMWeisSWhitneyEShapiroDRBeerePAPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279:1615–22.
8.
AnsellBJWatsonKEFogelmanAM. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA1999;282:2051–7.
9.
TraberMGKaydenHJ. Inhibition of cholesterol synthesis by mevinolin stimulates low-density lipoprotein receptor activity in human monocyte-derived macrophages. Atherosclerosis1984;52:1–11.
10.
KnoppRH. Drug treatment of lipid disorders. N Engl J Med1999;341: 498–511.
11.
GrundySM. Statin trials and goals of cholesterol-lowering therapy. Circulation1998;97:1436–9.
12.
PignoneMPhillipsCMulrowC. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomized trials. BMJ2000;321:983–6.
13.
2000 Drug topics red book. Montvale, NJ: Medical Economics, 2000.
14.
BieszkNKale-PradhanPB. The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free. Ann Pharmacother1999;33:638–41.
15.
PosadaISBarrialesV. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J1999;138:137–43.
16.
JabsKSullivanEKAvnerEDHarmonWE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation1996;61:31–6.
17.
GirvinBJohnstonGD. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens1998;16:1049–54.
18.
RindoneJPAchacosoRBledsoeR. Effect of lovastatin administered every other day on serum low-density lipoprotein cholesterol <160 mg/dl. Am J Cardiol1995;76:312–3.
19.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem1972;18:499–502.
20.
DennisVCBrittonMLSirmansSMLetassyNAFreemanDA. The use of alternate-day lovastatin in hypercholesterolemic men. Ann Pharmacother1997;31:708–12.
21.
RindoneJ PHillerDArriolaG. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacotherapy1998;18:836–9.
22.
KayikciogluMOzerkanFSoydanI. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol1999;83:1135–7.
23.
JafariMEbrahimiRBallianHOkamotoMAteshkadiA. Efficacy of alternate day dosing versus every day dosing with atorvastatin (abstract). Pharmacotherapy1999;19:1197.
24.
SchulzPTMoranKHoganTTMalcolmKZenniM. Evaluation of three methods of administering atorvastatin (abstract). Presented at the 34th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Orlando, FL, December 5–9, 1999.
